Canopy Growth Corporation
Canopy Growth Corporation CGC Peers
See (CGC) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CGC | $1.15 | -8.74% | 246.1M | -0.29 | -$4.09 | N/A |
| ZTS | $155.21 | -1.93% | 70.7B | 28.46 | $5.58 | +1.17% |
| TAK | $14.67 | -3.07% | 46.7B | 64.46 | $0.23 | +3.97% |
| HLN | $9.96 | -0.95% | 45.4B | 23.49 | $0.43 | +1.66% |
| TEVA | $16.29 | -2.49% | 18.9B | -14.37 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $134.20 | +0.52% | 13.4B | 45.73 | $2.95 | N/A |
| RDY | $14.51 | -1.73% | 12.2B | 18.59 | $0.79 | +0.65% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.14 | -0.98% | 10.9B | -2.91 | -$3.18 | +6.47% |
Stock Comparison
CGC vs ZTS Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ZTS has a market cap of 70.7B. Regarding current trading prices, CGC is priced at $1.15, while ZTS trades at $155.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ZTS's P/E ratio is 28.46. In terms of profitability, CGC's ROE is -1.13%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, CGC is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs TAK Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TAK has a market cap of 46.7B. Regarding current trading prices, CGC is priced at $1.15, while TAK trades at $14.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TAK's P/E ratio is 64.46. In terms of profitability, CGC's ROE is -1.13%, compared to TAK's ROE of +0.04%. Regarding short-term risk, CGC is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs HLN Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, HLN has a market cap of 45.4B. Regarding current trading prices, CGC is priced at $1.15, while HLN trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas HLN's P/E ratio is 23.49. In terms of profitability, CGC's ROE is -1.13%, compared to HLN's ROE of +0.09%. Regarding short-term risk, CGC is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs TEVA Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TEVA has a market cap of 18.9B. Regarding current trading prices, CGC is priced at $1.15, while TEVA trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TEVA's P/E ratio is -14.37. In terms of profitability, CGC's ROE is -1.13%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, CGC is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ITCI Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CGC is priced at $1.15, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CGC's ROE is -1.13%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs NBIX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, NBIX has a market cap of 13.4B. Regarding current trading prices, CGC is priced at $1.15, while NBIX trades at $134.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas NBIX's P/E ratio is 45.73. In terms of profitability, CGC's ROE is -1.13%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, CGC is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs RDY Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, RDY has a market cap of 12.2B. Regarding current trading prices, CGC is priced at $1.15, while RDY trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas RDY's P/E ratio is 18.59. In terms of profitability, CGC's ROE is -1.13%, compared to RDY's ROE of +0.18%. Regarding short-term risk, CGC is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs CTLT Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CGC is priced at $1.15, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CGC's ROE is -1.13%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, CGC is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs VTRS Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, VTRS has a market cap of 10.9B. Regarding current trading prices, CGC is priced at $1.15, while VTRS trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas VTRS's P/E ratio is -2.91. In terms of profitability, CGC's ROE is -1.13%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, CGC is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs RGC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, RGC has a market cap of 8.2B. Regarding current trading prices, CGC is priced at $1.15, while RGC trades at $14.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas RGC's P/E ratio is -1656.50. In terms of profitability, CGC's ROE is -1.13%, compared to RGC's ROE of -0.25%. Regarding short-term risk, CGC is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs ELAN Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ELAN has a market cap of 7.5B. Regarding current trading prices, CGC is priced at $1.15, while ELAN trades at $14.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ELAN's P/E ratio is 20.07. In terms of profitability, CGC's ROE is -1.13%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, CGC is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs LNTH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, LNTH has a market cap of 5.8B. Regarding current trading prices, CGC is priced at $1.15, while LNTH trades at $81.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas LNTH's P/E ratio is 22.97. In terms of profitability, CGC's ROE is -1.13%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, CGC is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs AMRX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, AMRX has a market cap of 3.9B. Regarding current trading prices, CGC is priced at $1.15, while AMRX trades at $8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas AMRX's P/E ratio is -210.00. In terms of profitability, CGC's ROE is -1.13%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs PRGO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, CGC is priced at $1.15, while PRGO trades at $27.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas PRGO's P/E ratio is -22.72. In terms of profitability, CGC's ROE is -1.13%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, CGC is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs HCM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, CGC is priced at $1.15, while HCM trades at $16.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas HCM's P/E ratio is 80.25. In terms of profitability, CGC's ROE is -1.13%, compared to HCM's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ALVOW Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ALVOW has a market cap of 2.6B. Regarding current trading prices, CGC is priced at $1.15, while ALVOW trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ALVOW's P/E ratio is N/A. In terms of profitability, CGC's ROE is -1.13%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, CGC is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs ALVO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ALVO has a market cap of 2.6B. Regarding current trading prices, CGC is priced at $1.15, while ALVO trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ALVO's P/E ratio is 23.62. In terms of profitability, CGC's ROE is -1.13%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, CGC is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs BHC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, CGC is priced at $1.15, while BHC trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas BHC's P/E ratio is -55.25. In terms of profitability, CGC's ROE is -1.13%, compared to BHC's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs DCPH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CGC is priced at $1.15, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CGC's ROE is -1.13%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, CGC is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs INDV Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, INDV has a market cap of 1.9B. Regarding current trading prices, CGC is priced at $1.15, while INDV trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas INDV's P/E ratio is -307.40. In terms of profitability, CGC's ROE is -1.13%, compared to INDV's ROE of -0.01%. Regarding short-term risk, CGC is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs EMBCV Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CGC is priced at $1.15, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CGC's ROE is -1.13%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, CGC is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs SUPN Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, CGC is priced at $1.15, while SUPN trades at $33.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SUPN's P/E ratio is 29.86. In terms of profitability, CGC's ROE is -1.13%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, CGC is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs BGM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, BGM has a market cap of 1.7B. Regarding current trading prices, CGC is priced at $1.15, while BGM trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas BGM's P/E ratio is -47.52. In terms of profitability, CGC's ROE is -1.13%, compared to BGM's ROE of -0.03%. Regarding short-term risk, CGC is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs TARO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CGC is priced at $1.15, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TARO's P/E ratio is 30.05. In terms of profitability, CGC's ROE is -1.13%, compared to TARO's ROE of +0.02%. Regarding short-term risk, CGC is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs EVO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, CGC is priced at $1.15, while EVO trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EVO's P/E ratio is -6.04. In terms of profitability, CGC's ROE is -1.13%, compared to EVO's ROE of -0.22%. Regarding short-term risk, CGC is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ANIP Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, CGC is priced at $1.15, while ANIP trades at $65.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ANIP's P/E ratio is -56.05. In terms of profitability, CGC's ROE is -1.13%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, CGC is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs DVAX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, CGC is priced at $1.15, while DVAX trades at $10.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas DVAX's P/E ratio is -21.78. In terms of profitability, CGC's ROE is -1.13%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, CGC is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs PAHC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, CGC is priced at $1.15, while PAHC trades at $30.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas PAHC's P/E ratio is 39.90. In terms of profitability, CGC's ROE is -1.13%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, CGC is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs FLXN Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, CGC is priced at $1.15, while FLXN trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas FLXN's P/E ratio is N/A. In terms of profitability, CGC's ROE is -1.13%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, CGC is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs HROW Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, CGC is priced at $1.15, while HROW trades at $34.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas HROW's P/E ratio is -51.38. In terms of profitability, CGC's ROE is -1.13%, compared to HROW's ROE of -0.36%. Regarding short-term risk, CGC is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs PCRX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, CGC is priced at $1.15, while PCRX trades at $23.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas PCRX's P/E ratio is -10.59. In terms of profitability, CGC's ROE is -1.13%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, CGC is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs COLL Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, CGC is priced at $1.15, while COLL trades at $32.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas COLL's P/E ratio is 27.06. In terms of profitability, CGC's ROE is -1.13%, compared to COLL's ROE of +0.19%. Regarding short-term risk, CGC is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs AMPH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, CGC is priced at $1.15, while AMPH trades at $21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas AMPH's P/E ratio is 8.05. In terms of profitability, CGC's ROE is -1.13%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, CGC is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs AVDL Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, AVDL has a market cap of 947.6M. Regarding current trading prices, CGC is priced at $1.15, while AVDL trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas AVDL's P/E ratio is -37.62. In terms of profitability, CGC's ROE is -1.13%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, CGC is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs PETQ Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CGC is priced at $1.15, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CGC's ROE is -1.13%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs CRON Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, CRON has a market cap of 811.3M. Regarding current trading prices, CGC is priced at $1.15, while CRON trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas CRON's P/E ratio is 15.04. In terms of profitability, CGC's ROE is -1.13%, compared to CRON's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs TLRY Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TLRY has a market cap of 662.4M. Regarding current trading prices, CGC is priced at $1.15, while TLRY trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TLRY's P/E ratio is -0.58. In terms of profitability, CGC's ROE is -1.13%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, CGC is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs EMBC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EMBC has a market cap of 627.6M. Regarding current trading prices, CGC is priced at $1.15, while EMBC trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EMBC's P/E ratio is 12.07. In terms of profitability, CGC's ROE is -1.13%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs EOLS Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EOLS has a market cap of 626.7M. Regarding current trading prices, CGC is priced at $1.15, while EOLS trades at $9.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EOLS's P/E ratio is -10.92. In terms of profitability, CGC's ROE is -1.13%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, CGC is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs BDSI Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CGC is priced at $1.15, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CGC's ROE is -1.13%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CGC is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ORGO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ORGO has a market cap of 558M. Regarding current trading prices, CGC is priced at $1.15, while ORGO trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ORGO's P/E ratio is -27.49. In terms of profitability, CGC's ROE is -1.13%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, CGC is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs SIGA Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SIGA has a market cap of 493.7M. Regarding current trading prices, CGC is priced at $1.15, while SIGA trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SIGA's P/E ratio is 10.31. In terms of profitability, CGC's ROE is -1.13%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, CGC is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs KMDA Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, KMDA has a market cap of 461.2M. Regarding current trading prices, CGC is priced at $1.15, while KMDA trades at $7.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas KMDA's P/E ratio is 28.64. In terms of profitability, CGC's ROE is -1.13%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, CGC is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs AQST Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, AQST has a market cap of 401.2M. Regarding current trading prices, CGC is priced at $1.15, while AQST trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas AQST's P/E ratio is -6.96. In terms of profitability, CGC's ROE is -1.13%, compared to AQST's ROE of +1.07%. Regarding short-term risk, CGC is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs EBS Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EBS has a market cap of 397.3M. Regarding current trading prices, CGC is priced at $1.15, while EBS trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EBS's P/E ratio is -2.84. In terms of profitability, CGC's ROE is -1.13%, compared to EBS's ROE of -0.27%. Regarding short-term risk, CGC is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs SNDL Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SNDL has a market cap of 364.1M. Regarding current trading prices, CGC is priced at $1.15, while SNDL trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SNDL's P/E ratio is -4.72. In terms of profitability, CGC's ROE is -1.13%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, CGC is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs LFCR Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, LFCR has a market cap of 325.3M. Regarding current trading prices, CGC is priced at $1.15, while LFCR trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas LFCR's P/E ratio is -5.98. In terms of profitability, CGC's ROE is -1.13%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, CGC is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ZYBT Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ZYBT has a market cap of 317M. Regarding current trading prices, CGC is priced at $1.15, while ZYBT trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ZYBT's P/E ratio is 111.50. In terms of profitability, CGC's ROE is -1.13%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, CGC is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs ALIM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CGC is priced at $1.15, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CGC's ROE is -1.13%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, CGC is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs TKNO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TKNO has a market cap of 277.9M. Regarding current trading prices, CGC is priced at $1.15, while TKNO trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TKNO's P/E ratio is -11.82. In terms of profitability, CGC's ROE is -1.13%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, CGC is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs ACB Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ACB has a market cap of 264.1M. Regarding current trading prices, CGC is priced at $1.15, while ACB trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ACB's P/E ratio is 21.34. In terms of profitability, CGC's ROE is -1.13%, compared to ACB's ROE of +0.00%. Regarding short-term risk, CGC is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs LNDC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CGC is priced at $1.15, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CGC's ROE is -1.13%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, CGC is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ESPR Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ESPR has a market cap of 245.8M. Regarding current trading prices, CGC is priced at $1.15, while ESPR trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ESPR's P/E ratio is -1.46. In terms of profitability, CGC's ROE is -1.13%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, CGC is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs TYHT Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CGC is priced at $1.15, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CGC's ROE is -1.13%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, CGC is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs OGI Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, OGI has a market cap of 196.1M. Regarding current trading prices, CGC is priced at $1.15, while OGI trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas OGI's P/E ratio is 11.27. In terms of profitability, CGC's ROE is -1.13%, compared to OGI's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs SXTC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SXTC has a market cap of 193.8M. Regarding current trading prices, CGC is priced at $1.15, while SXTC trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SXTC's P/E ratio is 0.01. In terms of profitability, CGC's ROE is -1.13%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, CGC is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs REPH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CGC is priced at $1.15, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas REPH's P/E ratio is -8.04. In terms of profitability, CGC's ROE is -1.13%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CGC is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs DERM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, DERM has a market cap of 168.5M. Regarding current trading prices, CGC is priced at $1.15, while DERM trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas DERM's P/E ratio is -19.55. In terms of profitability, CGC's ROE is -1.13%, compared to DERM's ROE of -0.52%. Regarding short-term risk, CGC is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs BIOA Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, BIOA has a market cap of 168M. Regarding current trading prices, CGC is priced at $1.15, while BIOA trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas BIOA's P/E ratio is -2.37. In terms of profitability, CGC's ROE is -1.13%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, CGC is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs THTX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, THTX has a market cap of 144.8M. Regarding current trading prices, CGC is priced at $1.15, while THTX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas THTX's P/E ratio is -16.58. In terms of profitability, CGC's ROE is -1.13%, compared to THTX's ROE of +0.16%. Regarding short-term risk, CGC is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs IRWD Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, IRWD has a market cap of 126.4M. Regarding current trading prices, CGC is priced at $1.15, while IRWD trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas IRWD's P/E ratio is -4.11. In terms of profitability, CGC's ROE is -1.13%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, CGC is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs SCTL Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CGC is priced at $1.15, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CGC's ROE is -1.13%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CGC is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs PROC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, CGC is priced at $1.15, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas PROC's P/E ratio is 1.53. In terms of profitability, CGC's ROE is -1.13%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CGC is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs CRDL Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, CRDL has a market cap of 112.4M. Regarding current trading prices, CGC is priced at $1.15, while CRDL trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas CRDL's P/E ratio is -4.00. In terms of profitability, CGC's ROE is -1.13%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, CGC is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs OPTN Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CGC is priced at $1.15, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CGC's ROE is -1.13%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, CGC is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ZOM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CGC is priced at $1.15, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CGC's ROE is -1.13%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, CGC is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs GRVI Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CGC is priced at $1.15, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CGC's ROE is -1.13%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, CGC is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs INCR Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, INCR has a market cap of 76.9M. Regarding current trading prices, CGC is priced at $1.15, while INCR trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas INCR's P/E ratio is -3.79. In terms of profitability, CGC's ROE is -1.13%, compared to INCR's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs ZYNE Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CGC is priced at $1.15, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CGC's ROE is -1.13%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CGC is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs ASRT Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ASRT has a market cap of 68M. Regarding current trading prices, CGC is priced at $1.15, while ASRT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ASRT's P/E ratio is -2.22. In terms of profitability, CGC's ROE is -1.13%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, CGC is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs SSIC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CGC is priced at $1.15, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CGC's ROE is -1.13%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, CGC is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs VLNS Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CGC is priced at $1.15, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CGC's ROE is -1.13%, compared to VLNS's ROE of N/A. Regarding short-term risk, CGC is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs QNTM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, QNTM has a market cap of 55.3M. Regarding current trading prices, CGC is priced at $1.15, while QNTM trades at $18.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas QNTM's P/E ratio is -1.44. In terms of profitability, CGC's ROE is -1.13%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, CGC is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs JUPW Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CGC is priced at $1.15, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CGC's ROE is -1.13%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, CGC is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs CPIX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, CPIX has a market cap of 48.9M. Regarding current trading prices, CGC is priced at $1.15, while CPIX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas CPIX's P/E ratio is -13.62. In terms of profitability, CGC's ROE is -1.13%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, CGC is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs EGRX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EGRX has a market cap of 46M. Regarding current trading prices, CGC is priced at $1.15, while EGRX trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EGRX's P/E ratio is 4.18. In terms of profitability, CGC's ROE is -1.13%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, CGC is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs KALA Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, KALA has a market cap of 44.5M. Regarding current trading prices, CGC is priced at $1.15, while KALA trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas KALA's P/E ratio is -0.94. In terms of profitability, CGC's ROE is -1.13%, compared to KALA's ROE of -3.69%. Regarding short-term risk, CGC is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs RMTI Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, RMTI has a market cap of 44.3M. Regarding current trading prices, CGC is priced at $1.15, while RMTI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas RMTI's P/E ratio is -129.50. In terms of profitability, CGC's ROE is -1.13%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, CGC is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs QLI Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CGC is priced at $1.15, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas QLI's P/E ratio is -4.92. In terms of profitability, CGC's ROE is -1.13%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CGC is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs HEXO Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CGC is priced at $1.15, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CGC's ROE is -1.13%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CGC is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs SCYX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SCYX has a market cap of 27.3M. Regarding current trading prices, CGC is priced at $1.15, while SCYX trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SCYX's P/E ratio is -1.25. In terms of profitability, CGC's ROE is -1.13%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, CGC is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs CYTH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CGC is priced at $1.15, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CGC's ROE is -1.13%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, CGC is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs IXHL Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, IXHL has a market cap of 20.8M. Regarding current trading prices, CGC is priced at $1.15, while IXHL trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas IXHL's P/E ratio is -0.18. In terms of profitability, CGC's ROE is -1.13%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, CGC is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs DRRX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, DRRX has a market cap of 19.1M. Regarding current trading prices, CGC is priced at $1.15, while DRRX trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas DRRX's P/E ratio is -1.28. In terms of profitability, CGC's ROE is -1.13%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, CGC is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs GELS Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, GELS has a market cap of 17.8M. Regarding current trading prices, CGC is priced at $1.15, while GELS trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas GELS's P/E ratio is -7.87. In terms of profitability, CGC's ROE is -1.13%, compared to GELS's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs PRPH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, PRPH has a market cap of 17.8M. Regarding current trading prices, CGC is priced at $1.15, while PRPH trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas PRPH's P/E ratio is -0.19. In terms of profitability, CGC's ROE is -1.13%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, CGC is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs FLGC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, FLGC has a market cap of 16M. Regarding current trading prices, CGC is priced at $1.15, while FLGC trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas FLGC's P/E ratio is -0.74. In terms of profitability, CGC's ROE is -1.13%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, CGC is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs ACRX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CGC is priced at $1.15, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CGC's ROE is -1.13%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, CGC is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs AYTU Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, AYTU has a market cap of 14.1M. Regarding current trading prices, CGC is priced at $1.15, while AYTU trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas AYTU's P/E ratio is -1.54. In terms of profitability, CGC's ROE is -1.13%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, CGC is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs TXMD Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TXMD has a market cap of 13.7M. Regarding current trading prices, CGC is priced at $1.15, while TXMD trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TXMD's P/E ratio is -6.24. In terms of profitability, CGC's ROE is -1.13%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, CGC is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs COSM Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, COSM has a market cap of 13.7M. Regarding current trading prices, CGC is priced at $1.15, while COSM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas COSM's P/E ratio is -0.43. In terms of profitability, CGC's ROE is -1.13%, compared to COSM's ROE of -0.51%. Regarding short-term risk, CGC is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs TLPH Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, TLPH has a market cap of 10.5M. Regarding current trading prices, CGC is priced at $1.15, while TLPH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas TLPH's P/E ratio is -1.16. In terms of profitability, CGC's ROE is -1.13%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, CGC is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs AGRX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CGC is priced at $1.15, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CGC's ROE is -1.13%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, CGC and AGRX have similar daily volatility (4.75).
CGC vs IMCC Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, IMCC has a market cap of 10.4M. Regarding current trading prices, CGC is priced at $1.15, while IMCC trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas IMCC's P/E ratio is -2.43. In terms of profitability, CGC's ROE is -1.13%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, CGC is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs SBFMW Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, SBFMW has a market cap of 9.1M. Regarding current trading prices, CGC is priced at $1.15, while SBFMW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas SBFMW's P/E ratio is -0.13. In terms of profitability, CGC's ROE is -1.13%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, CGC is less volatile compared to SBFMW. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs EVOK Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, EVOK has a market cap of 9.1M. Regarding current trading prices, CGC is priced at $1.15, while EVOK trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas EVOK's P/E ratio is -4.95. In terms of profitability, CGC's ROE is -1.13%, compared to EVOK's ROE of -1.02%. Regarding short-term risk, CGC is less volatile compared to EVOK. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs YCBD Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, YCBD has a market cap of 8.3M. Regarding current trading prices, CGC is priced at $1.15, while YCBD trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas YCBD's P/E ratio is 0.01. In terms of profitability, CGC's ROE is -1.13%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, CGC is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.
CGC vs NLTX Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CGC is priced at $1.15, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CGC's ROE is -1.13%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, CGC is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.
CGC vs BFRIW Comparison
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 246.1M. In comparison, BFRIW has a market cap of 7.9M. Regarding current trading prices, CGC is priced at $1.15, while BFRIW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.29, whereas BFRIW's P/E ratio is -0.08. In terms of profitability, CGC's ROE is -1.13%, compared to BFRIW's ROE of -2.16%. Regarding short-term risk, CGC is more volatile compared to BFRIW. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.